Global Reiter’s Syndrome Treatment Industry to 2027

company logo

Dublin, Sept. 28, 2022 (GLOBE NEWSWIRE) — The report “Reiter’s Syndrome Treatment Market – Global Industry Size, Share, Trends, Opportunities and Forecasts, 2017-2027” has been added to from ResearchAndMarkets.com offer.

The global Reiter’s syndrome treatment market is expected to grow at a significant CAGR during the forecast period 2023-2027. The growth of the market can be attributed to the increase in cases of reactive arthritis and advancements in treatment processes and methods. Additionally, advancements in the healthcare industry have led to better accessibility of care for patients suffering from serious diseases such as reactive arthritis, contributing to the growth of the global Reiter syndrome treatment market.

Reiter’s syndrome is a type of inflammatory arthritis, also known as reactive arthritis. The painful inflammation is caused by a bacterial infection. These bacteria are frequently found in the genital tract, such as Chlamydia trachomatis, or in the intestine, such as Campylobacter, Salmonella, Shigella and Yersinia. Genital bacteria are spread through sex and usually cause no noticeable symptoms. Purulent or watery discharge from the genitals is observed in some cases. Gut bacteria, on the other hand, usually cause diarrhea with discharge and can be considered a minor symptom of Reiter’s syndrome.

The rapid increase in the incidence of reactive arthritis and the growing demand for effective treatments are expected to drive the global Reiter’s syndrome treatment market over the next five years. Compared to other types of arthritis, reactive arthritis is a rare form. In 2021, more than 350 million arthritis patients are affected by Rieter syndrome. According to the CDC, arthritis affects approximately 24% of all adults in the United States. 58.5 million people. One in four adults has arthritis and suffers from severe joint pain.

Reiter’s syndrome affects approximately 27 in every 100,000 people worldwide, with adult males between the ages of 20 and 40 being the most affected. Growing population, rising instances of unprotected sex are increasing the chances of people getting the disease and contributing to the growth of the global Reiter’s syndrome treatment market over the next five years.

The global Reiter’s syndrome treatment market is segmented on the basis of drug type, dosage form, route of administration, distribution channel, end-user, regional distribution, and competitive landscape. Based on dosage form, the market is divided into tablets, injections and others. The tablets segment is expected to dominate the market over the forecast period, owing to their easier administration and increasing pharmaceutical development for the symptomatic treatment of Reiter’s syndrome.

Key players operating in the global Reiter’s syndrome treatment market are F. Hoffmann-La Roche AG, Pfizer, Inc., Novartis AG, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Abbott Laboratories, Inc., GlaxoSmithKline plc , Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd, AstraZeneca, Plc., among others.

Years considered for this report:

Goal of the study:

  • To analyze the historical growth in the global Reiter’s syndrome treatment market size from 2017 to 2023.

  • Estimate and forecast the global Reiter’s Syndrome Treatment market size from 2023 to 2027 and the growth rate till 2027.

  • To classify and forecast the global Reiter’s syndrome treatment market based on drug type, dosage form, route of administration, distribution channel, end-user, region, and company .

  • To identify the dominant region or segment in the global Reiter’s Syndrome Treatment Market.

  • To identify drivers and challenges in the global Reiter’s syndrome treatment market.

  • Examine competitive developments such as expansions, new product launches, mergers and acquisitions, etc., in the global Reiter’s syndrome treatment market.

  • To identify and analyze the profiles of key players operating in the global Reiter’s Syndrome Treatment Market.

  • To identify the key sustainable strategies adopted by market players in the global Reiter’s Syndrome Treatment Market.

Main topics covered:

1. Product introduction

2. Research methodology

3. Impact of COVID-19 on the Global Reiter’s Syndrome Treatment Market

4. Executive Summary

5. Voice of the customer
5.1. Preference, by drug type
5.2. Factors Contributing to Higher Demand for Reiter’s Syndrome Treatment
5.3. Barriers to uptake of treatment for Reiter’s syndrome
5.4. Brand awareness

6. Clinical trials
6.1. Ongoing clinical trials
6.2. Completed clinical trials
6.3. Completed clinical trials
6.4. Analysis of clinical trials

7. Patent analysis
7.1. Patent granted (2016-2020)
7.2. Patent applications filed

8. Global Reiter’s Syndrome Treatment Market Outlook
8.1. Market size and forecast
8.1.1. By value
8.2. Market share and forecasts
8.2.1. By drug type (antibiotics, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, others)
8.2.2. By dosage form (tablets, injections, others)
8.2.3. By route of administration (oral, intravenous, others)
8.2.4. By distribution channel (retail pharmacies, hospital pharmacies, online pharmacies)
8.2.5. By end user (hospitals and clinics, ambulatory care centers, others)
8.2.6. By company (2021)
8.2.7. By region
8.3. Commodity Market Map

9. North America Reiter’s Syndrome Treatment Market Outlook

10. Europe Reiter’s Syndrome Treatment Market Outlook

11. Asia Pacific Reiter’s Syndrome Treatment Market Outlook

12. South America Reiter’s Syndrome Treatment Market Outlook

13. Middle East & Africa Reiter’s Syndrome Treatment Market Outlook

14. Market Dynamics
14.1. Drivers
14.2. Challenges

15. Market trends and developments

16. Competitive landscape
16.1. F. Hoffmann-La Roche SA
16.2. Pfizer, Inc.
16.3. Novartis AG
16.4. Cipla inc.
16.5. Dr. Reddy’s Laboratories Ltd.
16.6. Abbott Laboratories, Inc.
16.7. GlaxoSmithKline plc
16.8. Sun Pharmaceutical Industries Ltd
16.9. Teva Pharmaceutical Industries Ltd
16.10. AstraZeneca, Plc.

17. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/p5q3en

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Comments are closed.